fda import alert green list glp-1 semaglutide tirzepatide 2025 Food and Drug Administration Issues API FDA Targets GLP-1 and Peptide

In fact, a 2023 study published in The Lancet found that among participants with prediabetes who were treated with tirzepatide, a significant proportion no longer met the criteria for prediabetes after just one year

Here is the practical framework for thinking through it

Ozempic and Wegovy are given as once-weekly subcutaneous injections

Advise reporting persistent abdominal pain (pancreatitis warning)

Side effect management drives a smaller but significant group of switchers

However, due to its high molecular weight and large structure, it is theorized that the milk concentration of tirzepatide is less, and absorption is unlikely to occur due to the breastfed infant's gastrointestinal tract [11]